TherapID™-KRAS test proposed by DNAVision identifies KRAS mutations that predict lack of response to several anti-cancer therapies targeting EGFR: Cetuximab, Panitumumab (in colorectal cancer) or Erlotinib, Gefitinib (in non small cell lung cancer). By restricting the use of these drugs to patients who have non-mutated KRAS genes, the likelihood to better respond to therapy will be increased. Mutated KRAS genes have been detected in about 40% of metastatic colorectal cancer patients, depending on the testing method used.
DNAVision is now offering KRAS mutation testing on paraffin-embedded clinical material (sample consists in paraffin primary tumor block and an HE glass slide). The test includes a histolopathology review of the sample to ensure tumor tissue is present. The assay uses PCR-based method, which is designed to detect every potentially activating mutations of the KRAS gene at codon 12 and 13 (which is not achievable with current commercially available kits). The assay is sensitive down to 2.5 % of mutant DNA in a background of wild type genomic DNA.
All oncologists can now ask their pathology laboratories to carry out testing on tumor samples to assess KRAS mutation status, and the results of these tests should be used to decide whether or not using an EGFR inhibitor therapy.
Samples consists in paraffin primary tumor block and an HE glass slide
1 week
A report will be generated including mutations that have been detected.
KRAS Testing : 200€ all included
Please inquire for ordering information.